We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
+20.66%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.64B
AUM Growth
+$352M
Cap. Flow
-$18.8M
Cap. Flow %
-0.71%
Top 10 Hldgs %
38.92%
Holding
218
New
26
Increased
62
Reduced
55
Closed
4

Top Buys

Rank Stock Value
1
REGN icon
Regeneron Pharmaceuticals
REGN
+$14M
2
JNJ icon
Johnson & Johnson
JNJ
+$13.4M
3
ABT icon
Abbott
ABT
+$12.5M
4
MIST icon
Milestone Pharmaceuticals
MIST
+$12.4M
5
CI icon
Cigna
CI
+$12M

Top Sells

Rank Stock Value
1
CELG
Celgene Corp
CELG
+$146M
2
UNH icon
UnitedHealth
UNH
+$23.1M
3
ISRG icon
Intuitive Surgical
ISRG
+$9.43M
4
HUM icon
Humana
HUM
+$9.27M
5
ZTS icon
Zoetis
ZTS
+$7.29M

Sector Composition

Rank Sector Weight
1 Healthcare 94.16%
2 Real Estate 3.23%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
INSM icon
126
Insmed
INSM
$22B
$3.94M 0.15%
164,786
– –
PTLA
127
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
$3.87M 0.15%
161,899
+46,451
+40% +$1.28M
DCPH
128
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$3.82M 0.14%
+61,370
New +$2.92M
FOLD
129
DELISTED
Amicus Therapeutics
FOLD
$3.59M 0.14%
368,960
+54,363
+17% +$498K
INGN icon
130
Inogen
INGN
$174M
$3.51M 0.13%
51,406
-10,120
-16% -$635K
MASI
131
DELISTED
Masimo
MASI
$3.44M 0.13%
21,773
-4,663
-18% -$701K
MTD icon
132
Mettler-Toledo International
MTD
$27.9B
$3.35M 0.13%
+4,223
New +$3.05M
FATE icon
133
Fate Therapeutics
FATE
$293M
$3.24M 0.12%
165,672
– –
ITCI
134
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$3.23M 0.12%
94,238
+66,690
+242% +$800K
CRL icon
135
Charles River Laboratories
CRL
$11.3B
$3.2M 0.12%
20,967
-4,100
-16% -$568K
ALC icon
136
Alcon
ALC
$33.9B
$3.13M 0.12%
55,369
– –
TBPH icon
137
Theravance Biopharma
TBPH
$873M
$3.05M 0.12%
117,725
+71,624
+155% +$1.39M
DHC
138
Diversified Healthcare Trust
DHC
$2.17B
$3.02M 0.11%
357,720
– –
HR
139
DELISTED
Healthcare Realty Trust Incorporated
HR
$2.79M 0.11%
83,629
+15,629
+23% +$518K
RARX
140
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
$2.62M 0.1%
55,829
– –
PACB icon
141
Pacific Biosciences
PACB
$460M
$2.55M 0.1%
495,495
– –
ENDP
142
DELISTED
Endo International plc
ENDP
$2.49M 0.09%
531,570
– –
QTNT
143
DELISTED
Quotient Limited Ordinary Shares
QTNT
$2.47M 0.09%
6,501
– –
HQY icon
144
HealthEquity
HQY
$8.44B
$2.36M 0.09%
31,810
– –
A icon
145
Agilent Technologies
A
$39.2B
$2.33M 0.09%
27,325
-6,700
-20% -$527K
STE icon
146
Steris
STE
$22.5B
$2.25M 0.09%
14,790
-9,683
-40% -$1.42M
CHRS icon
147
Coherus Oncology
CHRS
$227M
$2.25M 0.09%
125,146
-70,000
-36% -$1.29M
DGX icon
148
Quest Diagnostics
DGX
$25.9B
$2.25M 0.08%
21,025
-4,987
-19% -$520K
HOLX
149
DELISTED
Hologic
HOLX
$2.23M 0.08%
42,701
– –
EVH icon
150
Evolent Health
EVH
$358M
$2.09M 0.08%
231,027
– –
4 5
6
7 8

Similar funds

EST
EA Series Trust Havertown, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q4 2019 Portfolio in Review

As of Q4 2019, Tekla Capital Management held 218 positions worth $2.64B, up 15% from $2.29B the previous quarter. Its ten largest holdings account for 39% of the portfolio.

Tekla Capital Management's Q4 2019 filing shows 26 new, 62 increased, 55 reduced and 4 closed positions. Its largest new stake was Centene: 149,526 shares worth $9.4M. The largest sale was Celgene Corp, an estimated $146M.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, down from 95% a quarter earlier, followed by Real Estate.

  • Tekla Capital Management's largest Q4 2019 buy was Centene: 149,526 shares worth $9.4M.
  • Tekla Capital Management added most to Regeneron Pharmaceuticals in Q4 2019, an estimated $14M increase.
  • Tekla Capital Management's biggest Q4 2019 reduction was UnitedHealth, cutting an estimated $23.1M.
  • Tekla Capital Management fully exited Celgene Corp in Q4 2019, selling an estimated $146M.
  • Tekla Capital Management's ten largest holdings make up 39% of its $2.64B portfolio in Q4 2019.
  • Tekla Capital Management opened 26 new positions and closed 4 in Q4 2019.
  • Tekla Capital Management's portfolio value rose 15% quarter-over-quarter to $2.64B.

Based on Tekla Capital Management's 13F filing for Q4 2019, filed 13 Feb 2020.